Leerink Partners analyst Marc Goodman downgraded Relmada Therapeutics Inc (NASDAQ: RLMD) from Outperform to Market Perform with a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE